Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor cells and conduct a suite of myeloid antitumor functions.

Ronald Vale and Siddhartha Mukherjee are among the founders of the company, which debuted Wednesday with over $50 million in funding. Vale is executive director of the Howard Hughes Medical Institute (HHMI) Janelia Research campus; and Mukherjee chairs Myeloid Therapeutics Inc.’s SAB and serves as a Columbia University hematologist and oncologist. He is also a co-founder of Vor Biopharma Inc...